Oncology Position
- Thread starter anonymous
- Start date
-
- Tags
- None
Need to sell at least $20M just to cover the comp and benefits of the commercial team. That doesn't include any marketing or promotional expenditures.
scratch that, I forgot there's a revenue share with Sanofi. This will definitely be on the liability side of the ledger for the foreseeable future.
That is a good idea...... you may like not working until October, but once the drug is approved you are going to feel the HEAT. Your team has the highest salaries, and we all know it. Eylea runs this company. We are sick of all of the launch brands not making goal. Praluent is a joke.
Nice to have a few months of income while I looked for another gig. Good luck, suckers.
Oh Mickey, where is your other. And don't play stupid. I know U R so0o0 smart.
Only 1 territory currently open, how many will they have to backfill between now and launch? 30%, 40%?
How long before Merck has a NCCN recommendation for CSCC?
How long before Merck has a NCCN recommendation for CSCC?
C'mon everyone - why so down? Not the first time this has happened with a product. Happens to almost every company at some point. Next year at this time we'll be making a dent in the market. Maybe not huge but we'll get some business. Just hang on.
When approval delays happen to some companies, their people have other products to sell.
When delays happen to companies that don't have other products for their people to sell, the people go bye bye.
Doomed.
When delays happen to companies that don't have other products for their people to sell, the people go bye bye.
Doomed.
omg so glad I passed on this mess, I do miss Harold however
You will launch after FDA approval, assuming it happens.
NO worries people. Eyelea had a 3 month delay before launch. Kevzara reps were paid for an entire year, and made 100% bonus after they were hired, but before they launched, now oncology. History in Regeneron has been that you will be paid until your product hits. Those of us selling product and working our butts off will not make bonus because quotas have gone up so much to pay for your salary while you get to stay home.
Even after this product is approved, the Eyelea team is going to be carrying the note for a long, long, long time.
No hope for becoming revenue positive for at least 12 months after launch, if then. The indication is very small and the misc J code will limit providers who are willing to risk reimbursement on predominantly Medicare patients.
It has no future in the lung cancer marketplace. Merck owns that and BMS and Roche are catching the crumbs. In the running for WORST oncology launch ever. Provenge and Zaltrap currently hold that unflattering title.